# NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

> **NCT06331520** · PHASE3 · COMPLETED · sponsor: **Fudan University** · enrollment: 644 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting
- Highly Emetogenic Chemotherapy

## Interventions

- **DRUG:** Netupitant / Palonosetron Oral Capsule [Akynzeo]
- **DRUG:** Olanzapine
- **DRUG:** Dexamethasone Oral

## Key facts

- **NCT ID:** NCT06331520
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-30
- **Target enrollment:** 644 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331520, "NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06331520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*